Qureight's Fibr8 Biomarker Advances IPF Treatment in Phase 2 Trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a …

Read this Journal Watch article and more clinical summaries on NEJM Clinician.

An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.

Early clinical data this week provided support for a genetics-derived target in fatty liver disease and added to the evidence for allogeneic CAR T cell the...

People with alcohol-associated hepatitis are more likely to die from the disease if they use cannabis. A large multinational study just published in Alcohol: Clinical and Experimental Research is …

French drugmaker Pierre Fabre and China's XtalPi Holdings announced an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs …

People with alcohol-associated liver disease who received a liver transplant survived years longer than those who did not, but there are disparities in which patients receive a transplant. A large …

First joint Rome Foundation and IOIBD consensus provides clinical guidelines for managing IBS-like symptoms in inflammatory bowel disease patients in remission.

ORLANDO — Patients with post-acute syndromes that followed a viral infection deserve to be heard and validated, according to a speaker at ACR Convergence.'ACR asked me to talk about …

Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this …